XM无法为美国居民提供服务。
A
A

AstraZeneca


市场新闻

US natgas extends decline on lesser cooling demand

US natgas extends decline on lesser cooling demand By Rahul Paswan Sept 19 (Reuters) - U.S. natural gas futures extended their decline on Thursday on lower cooling demand due to forecasts for less warmer-than-normal weather than previously expected. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange fell 3.30 cents or 1.4% to $2.25 per million British thermal units (mmBtu) by 10:03 a.m.
A
N

US natgas slips over 1% in volatile trade on less cooling demand

UPDATE 1-US natgas slips over 1% in volatile trade on less cooling demand Adds closing price By Rahul Paswan Sept 18 (Reuters) - U.S. natural gas futures fell more than 1% on Wednesday in a volatile trading, on fewer warmer-than-normal weather forecasts than previously expected, even as production was slow to ramp up to match demand after Hurricane Francine.
A
N

US natgas slips over 1% in volatile trade on less cooling demand

US natgas slips over 1% in volatile trade on less cooling demand By Rahul Paswan Sept 18 (Reuters) - U.S. natural gas futures fell more than 1% on Wednesday in a volatile trading, on fewer warmer-than-normal weather forecasts than previously expected, even as production was slow to ramp up to match demand after Hurricane Francine. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange fell 2.7 cents or 1.2% to $2.30 per million British thermal units (mmBtu) by 11:0
A
N

AstraZeneca Says Fasenra Approved In US For Eosinophilic Granulomatosis With Polyangiitis

BRIEF-AstraZeneca Says Fasenra Approved In US For Eosinophilic Granulomatosis With Polyangiitis Sept 18 (Reuters) - AstraZeneca PLC AZN.L : FASENRA EGPA US FDA APPROVAL FASENRA APPROVED IN US FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS FDA APPROVAL BASED ON POSITIVE MANDARA PHASE III TRIAL RESULTS Source text for Eikon: ID:nRSR6617Ea Further
A

US natgas slips 2% as output rises after Hurricane Francine

UPDATE 1-US natgas slips 2% as output rises after Hurricane Francine Adds comment and closing price By Rahul Paswan and Brijesh Patel Sept 17 (Reuters) - U.S. natural gas futures fell 2% on Tuesday after hitting a more than two-month high earlier in the session , a s Gulf of Mexico producers slowly ramp up production after Hurricane Francine, easing concerns over supply and prompting some profit taking.
A
N

US natgas hits over two-month high on warmer weather, higher demand view

US natgas hits over two-month high on warmer weather, higher demand view By Rahul Paswan Sept 17 (Reuters) - U.S. natural gas futures rose to a more than two-month high on Tuesday, supported by higher demand forecasts for the next week and warmer weather outlook which could boost the amount of gas power generators burn. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange rose 5.2 cents or 2.2% to $2.43 per million British thermal units (mmBtu) at 10:16 a.m.
A
N

US natgas rises 3% on higher demand outlook, output cut

UPDATE 1-US natgas rises 3% on higher demand outlook, output cut Adds closing price, add details By Rahul Paswan Sept 16 (Reuters) - U.S. natural gas futures rose 3 % on Monday, buoyed by forecasts for higher demand over the next week, while the market also factored in production cuts due to last week's storm. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange rose 6.8 cents or 3% to settle at $2.373 per million British thermal units (mmBtu).
A
N

US natgas rises over 2% on higher demand outlook, supply woes

US natgas rises over 2% on higher demand outlook, supply woes By Rahul Paswan Sept 16 (Reuters) - U.S. natural gas futures rose more than 2% on Monday, buoyed by forecasts for higher demand over the next week, while the market also factored in production cuts due to last week's storm. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange rose 5.8 cents or 2.5% to $2.36 per million British thermal units (mmBtu) at 10:35 a.m.
A
N

Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line

UPDATE 1-Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line Adds details on supply in paragraphs 4 and 6, background throughout Sept 16 (Reuters) - Sanofi SASY.PA and partner AstraZeneca AZN.L have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory syncytial virus (RSV) therapy, the French drugmaker said on Monday.
A
S

US FDA approves manufacturing line for Sanofi's preventive RSV therapy

US FDA approves manufacturing line for Sanofi's preventive RSV therapy Sept 16 (Reuters) - Sanofi SASY.PA said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca's AZN.L preventive respiratory syncytial virus (RSV) therapy. Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswa
A
S

Imfinzi® (Durvalumab) Plus Imjudo® (Tremelimumab-Actl) Demonstrated Unprecedented Overall Survival In Advanced Liver Cancer With One In Five Patients Surviving Five Years In Himalaya Phase Iii Trial

BRIEF-Imfinzi® (Durvalumab) Plus Imjudo® (Tremelimumab-Actl) Demonstrated Unprecedented Overall Survival In Advanced Liver Cancer With One In Five Patients Surviving Five Years In Himalaya Phase Iii Trial Sept 16 (Reuters) - AstraZeneca PLC AZN.L : IMFINZI® (DURVALUMAB) PLUS IMJUDO® (TREMELIMUMAB-ACTL) DEMONSTRATED UNPRECEDENTED OVERALL SURVIVA
A

AstraZeneca's Imfinzi Plus Imjudo Demonstrated Overall Survival In Advanced Liver Cancer

BRIEF-AstraZeneca's Imfinzi Plus Imjudo Demonstrated Overall Survival In Advanced Liver Cancer Sept 16 (Reuters) - AstraZeneca PLC AZN.L : IMFINZI PLUS IMJUDO DEMONSTRATED UNPRECEDENTED OVERALL SURVIVAL IN ADVANCED LIVER CANCER WITH ONE IN FIVE PATIENTS SURVIVING FIVE YEARS IN HIMALAYA PHASE III TRIAL Source text for Eikon: ID:nWkr56t86z Further co
A

Astrazeneca Says Imfinzi Perioperative Regimen Reduced The Risk Of Recurrence By 32% And The Risk Of Death By 25%

BRIEF-Astrazeneca Says Imfinzi Perioperative Regimen Reduced The Risk Of Recurrence By 32% And The Risk Of Death By 25% Sept 15 (Reuters) - AstraZeneca PLC AZN.L : IMFINZI® (DURVALUMAB) PERIOPERATIVE REGIMEN REDUCED THE RISK OF RECURRENCE BY 32% AND THE RISK OF DEATH BY 25% VERSUS. NEOADJUVANT CHEMOTHERAPY ALONE IN MUSCLE-INVASIVE BLADDER CANCER I
A

US natgas drops on profit taking after hitting 2-month high

UPDATE 1-US natgas drops on profit taking after hitting 2-month high Adds analyst comment, closing prices By Sherin Elizabeth Varghese Sept 13 (Reuters) - U.S. natural gas futures fell on Friday, as traders took profits after prices rose to a two-month high early, supported by higher demand forecasts and a drop in output in recent days due to Hurricane Francine.
A
N

Moffitt Cancer Center Announces Strategic Collaboration With Astrazeneca To Accelerate Oncology Cell Therapies

BRIEF-Moffitt Cancer Center Announces Strategic Collaboration With Astrazeneca To Accelerate Oncology Cell Therapies Sept 13 (Reuters) - AstraZeneca PLC AZN.L : MOFFITT CANCER CENTER ANNOUNCES STRATEGIC COLLABORATION WITH ASTRAZENECA TO ACCELERATE ONCOLOGY CELL THERAPIES Source text for Eikon: ID:nBw9whrNpa Further company coverage: AZN.L
A

US natgas hits two-month high on output drop, higher demand view

US natgas hits two-month high on output drop, higher demand view By Sherin Elizabeth Varghese Sept 13 (Reuters) - U.S. natural gas futures rose to a two-month high on Friday, supported by higher demand forecasts and a drop in output in recent days as Hurricane Francine prompted oil and gas producers to cut production. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange were little changed at $2.36 per million British thermal units (mmBtu) at 10:27 a.m.
A
N

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an
A
B
F
J
R
R
S
P
F

European stocks wrap up week on a high note; focus shifts to Fed

UPDATE 2-European stocks wrap up week on a high note; focus shifts to Fed For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window France's inflation at 0.2% in Aug. AstraZeneca down after Deutsche Bank downgrades Worldline plunges on another guidance cut, CEO exit STOXX 600 up 0.7% Updated at 1550 GMT By Shubham Batra Sept 13 (Reuters) - European stocks rounded off the week on a positive note, supported by technology, real estate and mining shar
A
S
E
F
U
G

AstraZeneca hits more than 7-week low after Deutsche Bank downgrades

BUZZ-AstraZeneca hits more than 7-week low after Deutsche Bank downgrades ** Shares of AstraZeneca AZN.L fall 1.4% to 11,874 pence, lowest since July 24 ** AZN second biggest percentage loser on the benchmark FTSE 100 index .FTSE ** Deutsche Bank cuts rating to "sell" from "hold" and target price to 10,500p from 11,000p ** Twenty-one of 29 brokerag
A
U

Alstom, Siemens, Tesco

EUROPE RESEARCH ROUNDUP-Alstom, Siemens, Tesco Sept 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alstom, Siemens and Tesco, on Friday. HIGHLIGHTS * Alstom ALSO.PA : HSBC raises target price to EUR 26 from EUR 24 * Hexagon AB HEXAB.ST : HSBC cuts target price to SEK 110 from SEK 120 * Siemens AG SIEGN.DE : HSBC cuts target price to EUR 140 from EUR 150 * Tesco TSCO.L : Citigroup raises target price to 425p from 350p * Travis P
A
A
A
B
B
B
C
C
C
D
D
E
E
F
H
H
I
K
L
L
S
S
S
S
T
T
P
A
A
F
S
U



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明